Used in pharmaceutical research as a proteolysis targeting chimera (PROTAC) linker component, enabling targeted protein degradation. Demonstrates potential in oncology for modulating disease-causing proteins by facilitating their ubiquitination and subsequent degradation via the proteasome pathway. Exhibits cell permeability and stability in biological systems, making it suitable for in vitro and in vivo studies focused on cancer therapeutics. Also employed in the development of molecular glues and bifunctional molecules designed to induce protein-protein interactions for therapeutic intervention.